Angelini Ventures
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
MMI | Oct 2026Participated | $125 MSeries D | |
Rouge Therapeutics | Oct 2026Led | $58 MSeries A | |
Aptadir Therapeutics | Sep 2026Participated | $45 MSeed | |
MMI | Sep 2026Led | $20 MOther Equity | |
Epicrispr | Aug 2026Participated | $90 MSeries C | |
Handspring Health | Jul 2026Participated | $19 MSeries B | |
Cour Pharmaceuticals Development | Jun 2026Participated | $50 MSeries B | |
Rosso | Jun 2026Participated | $3 MSeed | |
Ema Health | Jun 2026Participated | $3 MSeed | |
NUCLIDIUM | May 2026Led | $33 MSeries B | |
Hypervision Surgical | Apr 2026Participated | $23 MSeries A | |
Laigo Bio | Mar 2026Participated | $19 MSeed | |
MMI | Oct 2026Participated | $125 MSeries D | |
Rouge Therapeutics | Oct 2026Led | $58 MSeries A | |
Aptadir Therapeutics | Sep 2026Participated | $45 MSeed | |
MMI | Sep 2026Led | $20 MOther Equity | |
Epicrispr | Aug 2026Participated | $90 MSeries C | |
Handspring Health | Jul 2026Participated | $19 MSeries B | |
Cour Pharmaceuticals Development | Jun 2026Participated | $50 MSeries B | |
Rosso | Jun 2026Participated | $3 MSeed | |
Ema Health | Jun 2026Participated | $3 MSeed | |
NUCLIDIUM | May 2026Led | $33 MSeries B | |
Hypervision Surgical | Apr 2026Participated | $23 MSeries A | |
Laigo Bio | Mar 2026Participated | $19 MSeed |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 5 |
| Series A | 5 | 5 |
| Series B | 4 | 3 |
| Series C+ | 0 | 5 |
| Other Equity | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 1 |
| Dec '23 | 1 |
| Jan '24 | 2 |
| Feb '24 | 1 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 2 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 2 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 1 |
| Jun '26 | 3 |
| Jul '26 | 1 |
| Aug '26 | 1 |
| Sep '26 | 2 |
| Oct '26 | 2 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 28 |
| Hardware & Robotics | 4 |
| AI & Machine Learning | 3 |
| Space & Frontier Tech | 3 |
| Networks, Cloud & Communication | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 4 |
| $5M-$10M | 1 |
| $10M-$25M | 8 |
| $25M-$50M | 8 |
| $50M-$100M | 6 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 16 |
| United States | 13 |
| Singapore | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Kurma Partners | 7 |
| CDP Venture Capital | 3 |
| Eurazeo | 3 |
| ROM Utrecht Region | 3 |
| 360 Capital Partners | 2 |
| Alpha Wave Ventures | 2 |
| ArgoBio | 2 |
| Asahi Kasei | 2 |
| Bayern Kapital | 2 |
| Bpifrance | 2 |
| Cancer Research Horizons | 2 |
| CDP Cassa Depositi e Prestiti | 2 |
| Ciapa Rosso | 2 |
| Club degli Investitori | 2 |
| Curie Capital | 2 |
| DeepTech & Climate Fonds | 2 |
| European Investment Bank | 2 |
| Evotec | 2 |
| Fintech Partners | 2 |
| H-Farm | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 11 | 37% |
| Participating | 19 | 63% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 9% |
| Co-led | 10 | 91% |
Team
Senior Associate
Principal
Chief Executive Officer & Managing Director
Managing Director
Chief Executive Officer